FDA puts a hold on Vertex’s attempted diabetes cure
Vertex thinks it has enough data to progress its experimental stem cell therapy for type 1 diabetes. The FDA has other thoughts.
The large biotech announced Monday that the agency put a hold on the clinical trial for the program, which grabbed “cure” headlines last year after Vertex released promising data from the first patient dosed in the study. The experimental treatment is designed to replace the insulin-producing cells T1D patients lose with lab-grown insulin-producing cells.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
